Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which promote the differentiation of monocytes via the nuclear receptor PPARγ. One of these substances was recently isolated and purified from oxLDL, and identified as azelaoyl PAF. Azelaoyl PAF is a potent PPARγ agonist which competes for the thiazolidinedione binding site. Azelaoyl PAF is more potent than 15-deoxy-δ12,14-prostaglandin J2, and equipotent with rosiglitazone as a ligand for this receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 3,850.00 |
Description | Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which promote the differentiation of monocytes via the nuclear receptor PPARγ. One of these substances was recently isolated and purified from oxLDL, and identified as azelaoyl PAF. Azelaoyl PAF is a potent PPARγ agonist which competes for the thiazolidinedione binding site. Azelaoyl PAF is more potent than 15-deoxy-δ12,14-prostaglandin J2, and equipotent with rosiglitazone as a ligand for this receptor. |
Molecular Weight | 651.863 |
Formula | C33H66NO9P |
CAS No. | 354583-69-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Ethanol: 20 mg/mL
PBS (pH 7.2): 10 mg/mL
DMSO: 8 mg/mL
DMF: 33 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Azelaoyl PAF 354583-69-0 inhibitor inhibit